Gallium hematoporphyrin

Gallium hematoporphyrin (GaHP) (0.5-1 μg/mL) inhibits growth of clinical M. abscessus isolates (including smooth and rough morphotypes) in iron-limited 7H9 media, with MICs of 0.5 and 1 μg/mL^[1].
Gallium hematoporphyrin (0.0625 μg/mL; in combination with clarithromycin) acts synergistically with clarithromycin against M. abscessus, with an FICI of 0.31 and an FIC of 0.0625 μg/mL for GaHP^[1].
Gallium hematoporphyrin (up to 32 μg/mL) is non-toxic to Vero E6 cells^[1].
Gallium hematoporphyrin (1 μg/mL (1.5 μM); 65 h) inhibits M. abscessus growth by targeting heme utilization pathways, as shown by growth rescue with hemin but not FAC at a GaHP concentration of 1 μg/mL (1.5 μM) over 65 h^[1].
Gallium hematoporphyrin (0.03-16 μg/mL; 3 h) induces concentration-dependent ROS production in M. abscessus at concentrations of 0.03 to 8 μg/mL after 3 h of incubation, with reduced ROS at 16 μg/mL due to cell death^[1].
Gallium hematoporphyrin (8 μg/mL) inhibits biofilm formation by smooth and rough M. abscessus morphotypes in iron-rich media, with ~60% inhibition of smooth variants and ~30% inhibition of rough variants^[1].
]Gallium hematoporphyrin (16 μg/mL) disrupts preformed biofilms of smooth and rough M. abscessus morphotypes, with ~50% disruption of smooth variant biofilms and ~40% disruption of rough variant biofilms^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.